News | April 11, 2012

Boston Scientific Launches Ingenio Pacemakers in Europe

Devices designed to treat chronotropic incompetence, which affects up to 42 percent of pacemaker patients

April 11, 2012 — Boston Scientific Corp. announced the CE mark approval and European market launch of its Ingenio and Advantio pacemakers and Invive cardiac resynchronization therapy pacemakers (CRT-P). One of the first implants of the Ingenio pacemaker occurred last week by Marc Burban, M.D., at the Nouvelles Cliniques Nantaises in Nantes, France.

“The Ingenio family of pacemakers represents a significant investment in long-term innovation for pacing technologies and defines a new era of pacing for our company,” said Joe Fitzgerald, senior vice president and president of the Boston Scientific Cardiac Rhythm Management group. “In addition, we expect to launch a series of devices with expanded capabilities that would include remote monitoring, advanced heart failure diagnostics and compatibility with magnetic resonance imaging systems – all designed to provide innovative new features for patient health and well-being.”

Pacemakers are designed to treat bradycardia, a condition in which the heart beats too slowly – usually less than 60 beats per minute – depriving the body of sufficient oxygen. The Ingenio and Advantio pacemakers also feature RightRate pacing technology designed to treat chronotropic incompetence (CI). CI is the inability of the heart to regulate its rate appropriately in response to physical activity, which may cause patients to feel tired or short of breath during daily activities such as walking or going up a flight of stairs. RightRate employs Boston Scientific’s minute ventilation (MV) sensor, clinically proven to restore chronotropic competence, and adds programming options to promote ease of use and in-clinic time savings.

“The Ingenio device enables physicians to treat pacemaker patients with an advanced and comprehensive set of therapies,” said Burban. “The new RightRate pacing is easy to optimize and is designed to provide needed heart rates for patients to help them feel less fatigued during physical activity.”

The Ingenio family of pacemakers and CRT-Ps is expected to be compatible with Boston Scientific’s new Latitude NXT Remote Patient Management system, which would enable physicians to conduct remote follow-ups of these device patients to monitor specific pacemaker information and heart health status. The system is designed to detect clinical events between scheduled visits and send relevant data directly to a secure physician-accessible website via landline or cellular-based telephone technology.

The Ingenio and Advantio pacemakers are currently under review by the U.S. Food and Drug Administration and not available for sale in the United States.

For more information: www.bostonscientific.com

Related Content

Abbott Secures FDA Approval for MRI Compatibility on Ellipse ICD
Technology | Implantable Cardioverter Defibrillator (ICD)| September 22, 2017
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Fysicon Receives FDA Approval for QMAPP Hemodynamic Monitoring System
Technology | Hemodynamic Monitoring Systems| September 18, 2017
Fysicon announced that it has been granted 510(k) clearance by the U.S. Food and Drug Administration (FDA) for its...
Technavio Projects 9 Percent Global Growth for Electrophysiology Therapeutic Devices

Image courtesy of Technavio

News | EP Lab| September 11, 2017
September 11, 2017 — According to the latest market study released by Technavio, the global...
EMANATE Trial Shows Apixaban Lowers stroke in AF Patients Undergoing Cardioversion.
News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with at
CASTLE-AF Study shows Catheter Ablation of Atrial Fibrillation is First-Line Treatment for Heart Failure Patients. Biotronic Ilivia 7 ICD.

The CASTLE-AF Study shows catheter alation of AF can be used effectively to treat heart failure in patients with an implanted ICD.

News | Atrial Fibrillation| September 01, 2017
September 1, 2017 — Final results from the CASTLE-AF study show a 38 percent reduction in the composite of all-cause
Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices

Abbott. St. Jude Medical has updated its firmware to address cybersecurity issues with its Allure Quadra MP and other EP devices.

Feature | EP Lab| August 29, 2017 | Dave Fornell
August 29, 2017 — The U.S.
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Overlay Init